Modulators of androgen and estrogen receptor activity

Critical Reviews in Eukaryotic Gene Expression

Volumn 20, Issue 4, 2010, Pages 275-294

  Clarke, Bart L ^a   Khosla, Sundeep ^a  

^a MAYO CLINIC   (United States)

Author keywords

Arzoxifene; Bazedoxifene; Breast cancer; Lasofoxifene; Osteoporosis; Prostate cancer; Raloxifene; SARM; SERM; Tamoxifen

Indexed keywords

ACP 105; ANDROGEN RECEPTOR; ANTIANDROGEN; ARZOXIFENE; BAZEDOXIFENE; BICALUTAMIDE; BMS 564929; FLUTAMIDE; FULVESTRANT; GLUCOCORTICOID; HMR 3339; JNJ 37654032; LASOFOXIFENE; LGD 2941; LGD 3303; NILUTAMIDE; OSPEMIFENE; PIPENDOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; TRENBOLONE; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST; ESTROGEN RECEPTOR;

ACNE; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG INTERACTION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HIRSUTISM; HOT FLUSH; HUMAN; LEG CRAMP; LIVER TOXICITY; NIGHT SWEAT; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; SIGNAL TRANSDUCTION; STROKE; VENOUS THROMBOEMBOLISM; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG EFFECT; FEMALE; MALE; PROSTATE TUMOR; REVIEW;

ANDROGEN RECEPTOR ANTAGONISTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RALOXIFENE; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 79955005388     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v20.i4.10     Document Type: Article

References (81)

1. Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J. 2008 Jan-Feb;14(1):11-4.
2. Gao W, Dalton JT. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5α-reductase? Mol Interv. 2007 Feb;7(1):10-3.
3. Shelly W, Draper MW, Krishnan V, Wong M, Jafe RB. Selective estrogen receptor modulators: an update on recent clinical fndings. Obstet Gynecol Surv. 2008 March;63(3):163-81.
4. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst. 2007 March 7;99(5):350-6.
5. Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol. 2010 Mar 17;72:247-72.
6. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010. Epub. 2008 Nov 26.
7. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009 Jun;30(4):343-75.
8. Wright AS, Douglas RC, Tomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology. 1999 Oct;140(10):4509-15.
9. Parent EE, Jenks C, Sharp T, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of a non-steroidal bromine-76-labelled androgen receptor ligand 3-(76Br)bromo-hydroxyfutamide. Nucl Med Biol. 2006 Aug;33(6):705-13.
10. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal li-gands in the androgen receptor. J Biol Chem. 2005 Nov 11;280(4):37747-54.
11. Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Bee-hler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology. 2007 Jan;148(1):4-12.
12. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafs-son JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16;389(6652):753-8.
13. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell. 2005 May 13;18(4):412-24.
14. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Rev. 2007 Dec;28(7):778-808.
15. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specifcity of selective receptor modulators. Endocrine Rev. 2004 Jan;25(1):45-71.
16. Ting HJ, Chang C. Actin associated proteins function as androgen receptor coregulators: an implication of androgen receptor's roles in skeletal muscle. J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):157-63.
17. Gao W, Bohl CE, Dalton J T. Chemistry and structural biology of androgen receptor. Chem Rev. 2005 Sept;105(2):3352-70.
18. Cadilla R, Turnbull P. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem. 2006;6(3):245-70.
19. Gao W, Kim J, Dalton J T. Pharmacokinetics and phar-macodynamics of nonsteroidal androgen receptor ligands. Pharm Res. 2006 Aug;23(8):1641-58.
20. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab. 1999;84: 3459-62.
21. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009 May;12(3):232-40.
22. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):146-59.
23. Dalton J T, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of nonsteroidal antiandrogens. Biochem Biophys Res Comm. 1998 Mar 6;244(1):1-4.
24. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifuoromethyl)-2(1H)-pyrrolidino(3,2g) quinolinone. Bioorg Med Chem Lett. 1998 Apr 7;8(7): 745-50.
25. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Phar-macodynamics of selective androgen receptor modulators. J Pharmacol Exp Terapeut. 2003 Mar;304(3):1334-40.
26. Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic efects of S-40503, a novel nonsteroidal androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharmacol Bull. 2003 Nov;26(11): 1563-9.
27. Allan G, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Ng R, Sui Z, Lundeen S. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):207-13.
28. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rut-ledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Dug-gan ME, Rodan GA, Towler DA, Ray WJ. Identifca-tion of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem. 2009 Dec 25;284(52): 36367-76.
29. Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, Fejzic A, Tygesen MB, Tabatabaei A, Bradley SR, Gardell LR, Piu F, Olsson R. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem. 2009 Nov 26;52(22):7186-91.
30. Riedmaier I, Tichopad A, Reiter M, Pfaf MW, Meyer HH. Infuence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73.
31. Vajda EG, Hogue A, Grifths KN, Chang WY, Burnett K, Chen Y, Marschke K, Mais DE, Pedram B, Shen Y, van Oeveren A, Zhi L, López FJ, Meglasson MD. Combination treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive efects in osteopenic female rats. J Bone Miner Res. 2009 Feb;24(2):231-40.
32. Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifuoroethyl)-3H-pyrrolo-[3,2-f]quin-olin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ter. 2009 Feb;328(2):663-70.
33. Kearbey JD, Gao W, Fisher SJ, Wu D, Miller DD, Dal-ton J T. Efects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats. Pharm Res. 2009 Nov;26(11):2471-7.
34. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton J T. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008 Nov;22(11):2448-65.
35. Nirschl AA, Zou Y, Krystek SR Jr, Sutton JC, Simpkins LM, Lupisella JA, Kuhns JE, Seethala R, Golla R, Sleph PG, Beehler BC, Grover GJ, Egan D, Fura A, Vyas VP, Li YX, Sack JS, Kish KF, An Y, Bryson JA, Gougoutas JZ, DiMarco J, Zahler R, Ostrowski J, Hamann LG. N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem. 2009 May 14;52(9):2794-8.
36. Zhao S, Shen Y, van Oeveren A, Marschke KB, Zhi L. Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3431-5.
37. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally-active selective androgen receptor modulator is efcacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
38. Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010 Jun;75(6):377-89.
39. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton J T. Efects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 2010 Aug;151(8): 3706-19.
40. Jones A, Hwang DJ, Duke CB, He Y, Siddam A, Miller DD, Dalton J T. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ter. 2010 Aug;334(2):439-48.
41. Smith CL, Nawaz Z, O'Malley BW. Coactivator and core-pressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997 Jun;11(6):657-66.
42. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufciency in estrogen receptor-regulated transcription. Cell. 2000 Dec 8;103(6): 843-52.
43. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endo-crinol. 1995 Jun;9(6):659-69.
44. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. Te structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7): 927-37.
45. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997 Jun 12;387(6634):733-6.
46. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profling and endocrine actions of tibolone. Steroids. 2003 Jan;68(1):21-30.
47. Billon-Galés A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, Gourdy P, Lenfant F, Laurell H, Krust A, Chambon P, Arnal JF. Te transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):2053-8.
48. Zwart W, de Leeuw R, Rondaij M, Neefes J, Mancini MA, Michalides R. Te hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estra-diol and tamoxifen. J Cell Sci. 2010 Apr 15;123(Pt 8): 1253-61.
49. Dickey RP, Holtkamp DE. Development, pharmacology, and clinical experience with clomiphene citrate. Hum Reprod Update. 1996 Nov-Dec;2(6):483-506.
50. Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, Agnusdei D, Stuenkel CA. Raloxifene use in clinical practice: efcacy and safety. Menopause. 2009 Mar-Apr;16(2):413-21.
51. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 2009 Feb 15;69(4):1243-54.
52. Pickar JH, Macneil T, Ohleth K. SERMs: Progress and future perspectives. Maturitas. 2010 Oct;67(2):129-38.
53. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specifcity and transcript tissue distribution of estrogen receptors ERα and β. Endocrinology. 1997 Mar;138(3): 863-70.
54. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Efects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997 Dec 4;337(23):1641-7.
55. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999 Aug 18;282(7):637-45.
56. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. Te efect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 Jun 16; 281(23):2189-97.
57. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK; Raloxifene Use for Te Heart (RUTH) Trial Investigators. Efects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006 Jul 13;355(2):125-37.
58. Vogel VG, Constantino JP, Wickerham JP, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Efects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA. 2006 Jun 21;295(23):2727-41.
59. Gushima M, Kawate H, Ohnaka K, Nomura M, Ta-kayanagi R. Raloxifene induces nucleolar translocation of the estrogen receptor. Mol Cell Endocrinol. 2010 May 5;319(1-2):14-22.
60. Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Efect of raloxifene on all-cause mortality. Am J Med. 2010 May;123(5):469.e1-7.
61. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ. Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, doubleblind, placebo-controlled trial. Eur J Endocrinol. 2010 Feb;162(2):371-6.
62. Jacobsen DE, Samson MM, Emmelot-Vonk MH, Verhaar HJ. Raloxifene improves verbal memory in late postmeno-pausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2010 Mar;17(2):309-14.
63. Zhang Y, Saha S, Rosenfeld G, Gonzalez J, Pepeljugoski KP, Peeva E. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice. J Rheumatol. 2010 Aug 1;37(8):1646-57.
64. McClung MR, Siris E, Cummings S, Bolognese M, Et-tinger M, Mofett A, Emkey R, Day W, Somayaji V, Lee A. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006 May-Jun;13(3):377-86.
65. Rogers A, Glover SJ, Eastell R. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone. 2009 Dec;45(6):1044-52.
66. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Tompson J, Armstrong RA, Tompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R; PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010 Feb 25;362(8):686-96.
67. Deshmane VL, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzox-ifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007 Nov 1;25(31): 4967-73.
68. Downs RW Jr, Mofett AM, Ghosh A, Cox DA, Dowsett SA, Harper K. Efects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporos Int. 2010 Jul;21(7):1215-26.
69. Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M. Efects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. J Clin Endocrinol Metab. 2009 Jul;94(7):2284-9.
70. Palacios S. Efcacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2010 Jul;26(7):1553-63.
71. Christiansen C, Chesnut CH 3rd, Adachi JD, Brown JP, Fernandes CE, Kung AW, Palacios S, Levine AB, Chines AA, Constantine GD. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010 Jun 22;11(1):130.
72. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2010 Jun 10. [Epub ahead of print]
73. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, Mc-Masters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer. 2010 May 15;116(10):2307-15.
74. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stål O, Linn S, Landberg G. Estrogen receptor-alpha phos-phorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9.
75. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kufel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7;302(13):1429-36.
76. Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, Hayes DF, Stearns V. Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer. 2010 Jan 19;102(2):294-300.
77. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Efects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsycho-logical side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010 Mar 10;28(8): 1294-300.
78. Johnston SJ, Cheung KL. Fulvestrant - a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17(10):902-14.
79. Chambliss KL, Wu Q, Ottmann S, Konaniah ES, Umetani M, Korach KS, Tomas GD, Mineo C, Yuhanna IS, Kim SH, Madak-Erdogan Z, Maggi A, Dineen SP, Roland CL, Hui DY, Brekken RA, Katzenellenbogen JA, Katzenellenbogen BS, Shaul PW. Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010 Jul 1;120(7): 2319-30.
80. Todorova VK, Kaufmann Y, Luo S, Klimberg VS. Tamox-ifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol. 2010 Apr 11. [Epub ahead of print]
81. DuSell CD, Nelson ER, Wittmann BM, Fretz JA, Kazmin D, Tomas RS, Pike JW, McDonnell DP. Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol. 2010 Jan;24(1):33-46.